Drug profile · INN
anacaulase-bcdb
NEXOBRID
anacaulase-bcdb (NEXOBRID) is a removal of necrotic tissue. Route of administration: topical. Current US regulatory status: approved.
Drug details — anacaulase-bcdb
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
anacaulase-bcdb (NEXOBRID) is a removal of necrotic tissue. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Removal of necrotic tissue
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is anacaulase-bcdb?
anacaulase-bcdb (NEXOBRID) is a removal of necrotic tissue. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for anacaulase-bcdb?
NEXOBRID is a marketed brand name for anacaulase-bcdb. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anacaulase-bcdb?
anacaulase-bcdb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.